leadf
logo-loader
viewAgile Therapeutics

Agile Therapeutics reveals data from comparative wear study on its contraceptive patch Twirla

Agile Therapeutics Inc (NASDAQ:AGRX) CEO Al Altomari sat down with Proactive Investors at the BIO CEO and Investor Conference in New York.

Agile's product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.

Quick facts: Agile Therapeutics

Price: 2.23 USD

NASDAQ:AGRX
Market: NASDAQ
Market Cap: $195.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Agile Therapeutics named herein, including the promotion by the Company of Agile Therapeutics in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Agile Therapeutics commercially launches its women's contraceptive patch...

Agile Therapeutics, Inc. (NASDAQ:AGRX) CEO Al Altomari tells Proactive the Princeton, New Jersey-based women’s healthcare company has commercially launched its low-dose, non-daily contraceptive patch for women named Twirla. Altomari says the group has built a system that can adapt to business...

on 12/09/2020

2 min read